Three Biotech Stocks That Could Double by '08
The biotech sector is an exciting space. There is always hope that you might discover the next Amgen (AMGN) or Celgene (CELG) before everyone else. I selected three biotech stocks that could double on any positive news. I should mention that there is also a greater than 50% chance that the stocks I am about to mention could lose half or all of their value by the end of the year.
1. Medarex (MEDX): This stock has been mentioned on various programs and websites as a possible takeover target with over 30 drugs in pipeline. Almost every drug that Medarex is developing is in some form of partnership with big pharma. I wouldn't be surprised if a partner like Bristol-Myers (BMY) buys them. More importantly, Medarex will present June 1st - June 5th at the ASCO conference in Chicago. There have been some leaks that the data from Medarex's Melanoma drug (MDX-010) will be good. I also like the fact that Will Dannoff of the Fidelity Contra Fund is the largest shareholder. He has spotted past winners in New River Pharma, Genentech, and Celgene.
2. Dendreon (DNDN): This could be the most talked about stock of 2007. Lots of folks are betting against this one with over 40% of the float short. The stock has already fallen from its recent high of $25 a share. The company is more of a one hit wonder when compared to Medarex. Dendreon's prostate cancer drug Provenge is in high demand and has proven to extend life for several months. Instead of buying the common I suggest taking a look at the January 2008 $7.50 calls for $1.60.
3. Isolagen (ILE): This stock has not received much attention from the media. Isolagen is currently developing a procedure that rejuvenates your facial skin. Skin cells are taken from behind your ear and then taken to a lab. After about a month the cells are injected back into your face. It is a natural form of Botox that can last up to 2 years. Isolagen appointed Nicholas Teti as the CEO in June of 2006. He was the CEO of Inamed until it was bought out by Allergan (AGN) last year.
Note: I am long MEDX
1. Medarex (MEDX): This stock has been mentioned on various programs and websites as a possible takeover target with over 30 drugs in pipeline. Almost every drug that Medarex is developing is in some form of partnership with big pharma. I wouldn't be surprised if a partner like Bristol-Myers (BMY) buys them. More importantly, Medarex will present June 1st - June 5th at the ASCO conference in Chicago. There have been some leaks that the data from Medarex's Melanoma drug (MDX-010) will be good. I also like the fact that Will Dannoff of the Fidelity Contra Fund is the largest shareholder. He has spotted past winners in New River Pharma, Genentech, and Celgene.
2. Dendreon (DNDN): This could be the most talked about stock of 2007. Lots of folks are betting against this one with over 40% of the float short. The stock has already fallen from its recent high of $25 a share. The company is more of a one hit wonder when compared to Medarex. Dendreon's prostate cancer drug Provenge is in high demand and has proven to extend life for several months. Instead of buying the common I suggest taking a look at the January 2008 $7.50 calls for $1.60.
3. Isolagen (ILE): This stock has not received much attention from the media. Isolagen is currently developing a procedure that rejuvenates your facial skin. Skin cells are taken from behind your ear and then taken to a lab. After about a month the cells are injected back into your face. It is a natural form of Botox that can last up to 2 years. Isolagen appointed Nicholas Teti as the CEO in June of 2006. He was the CEO of Inamed until it was bought out by Allergan (AGN) last year.
Note: I am long MEDX
posted by Big Ben at Tuesday, May 22, 2007
4 Comments:
Understanding investment banking with biotech stocks is complicated. BiotechIndustryStocks.com is an investor and industry news portal for the Biotech and Pharmaceutical sector. The BIS website does not make recommendations, but offers news, exclusive articles and columnists, audio interviews, investor conferences, blogs, and a list of stocks in the sector.
please review your performance expectations on all 3.... they blew.
Thanks on your marvelous posting! I certainly enjoyed reading it, you will be a great Author. I will remember to bookmark your blog and will eventually come back from now on. I want to encourage that you continue your great writing, have a nice day!
Profit
The biotech sector is an exciting space. There is always hope that you might discover the next Amgen (AMGN) or Celgene (CELG) before everyone else.With this blog you really took our attention to the points that we never thought about. Thanks for sharing this with all of us. All the best, way to go
Stock Tips
Post a Comment
<< Home